To read the full story, subscribe or sign in.

ZymoGenetics Starts Pivotal rhThrombin Phase III Study

Oct. 28, 2005

Nearly three months after raising $135 million to move its lead blood-clotting agent into a pivotal study, ZymoGenetics Inc. started the Phase III trial of recombinant human Thrombin (rhThrombin) in surgery patients. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for May 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...

Concept art for "unlocking the secrets of the mind"

New assay for drug discovery against chemo-induced peripheral neuropathy

BioWorld Science

A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity...

Hantavirus zoonotic spillover illustration

First cruise ship hantavirus genome points to zoonotic spillover

BioWorld

The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...